Konakion Mm Paediatric Ampoules

Phytomenadione, the active ingredient in Konakion Mm Paediatric Ampoules, is a vitamin K presented as an injectable solution for intramuscular, intravenous or oral use. It is employed to prevent and treat vitamin K deficiency bleeding, particularly in newborns, and to reverse anticoagulation caused by warfarin. GNH USA supplies Konakion Mm Paediatric Ampoules as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Konakion Mm Paediatric Ampoules provides vitamin K to address disorders of coagulation. - Hemorrhagic disease of the newborn: prevents bleeding in neonates at risk of vitamin K deficiency. - Vitamin K deficiency bleeding: treats active bleeding in infants and children with low vitamin K levels. - Warfarin reversal: restores clotting factor activity in patients requiring rapid anticoagulation reversal. - Surgical prophylaxis: reduces peri‑operative bleeding in patients with impaired vitamin K status.

Adverse reactions may occur following administration of vitamin K injectable solutions.

Common Side Effects: - Injection site pain or erythema - Mild nausea - Transient headache - Low‑grade fever - Diarrhoea - Dizziness

Serious or Rare Side Effects: - Anaphylactic reaction - Severe hypotension - Hemolysis - Jaundice - Thrombocytopenia - Persistent vomiting

When using Konakion Mm Paediatric Ampoules, consider the following precautions. - Contraindication: Do not use in patients with known hypersensitivity to phytomenadione or formulation excipients. - Caution in newborns: Monitor for signs of hyperbilirubinemia after administration. - Interaction with anticoagulants: Adjust dosing of concurrent warfarin therapy as needed. - Use in pregnancy: Evaluate risk‑benefit ratio; limited data available. - Storage: Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Phytomenadione may interact with other medicines affecting coagulation.

Major Interactions (Avoid): - Warfarin: can diminish anticoagulant effect, leading to loss of therapeutic control. - Broad‑spectrum antibiotics (e.g., cephalosporins): may interfere with vitamin K synthesis, requiring careful monitoring.

Moderate Interactions (Monitor Closely): - Rifampin: may increase vitamin K metabolism, reducing efficacy. - Phenobarbital: induces hepatic enzymes that accelerate vitamin K clearance. - Oral contraceptives: potential additive effect on clotting factors, warranting observation.